Avant Brands Terminates Trademark Licensing Agreement with Adjupharm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy IMCC?
Avant Brands' wholly-owned subsidiary, GreenTec Holdings, has issued a formal notice of termination for its Trademark Licensing Agreement with Adjupharm, a subsidiary of IM Cannabis Corp. The Agreement was originally announced on May 1, 2024.The decision comes as Avant initiates a broader strategic transition to optimize its international distribution channels and ensure its partnerships are fully synchronized with the Company's long-term global growth strategy. Effective May 31, 2026, all trademark and distribution rights for the blk mkt brand in Germany and Switzerland will revert to GreenTec. Germany represents Avant's largest international export market, as reported in the Company's Fiscal 2025 results. Following the formal termination notice, Avant has initiated an official process to identify a partner capable of maximizing the Company's established momentum in Germany. The Company is vetting established distributors and operators based on market leadership, fiscal & operational maturity and strategic infrastructure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCC
About IMCC
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IM Cannabis Reports Q1 Earnings Results
- Earnings Report: IM Cannabis reported a Q1 GAAP EPS of -$0.38, indicating challenges in profitability and reflecting pressure in a highly competitive market environment.
- Revenue Performance: The company generated revenue of $8.7 million, which, while showing some sales, falls short of industry expectations, potentially undermining investor confidence in future growth prospects.
- Nasdaq Notice: IM Cannabis received a notice from Nasdaq regarding minimum bid price requirements, which could negatively impact its stock liquidity and market perception, forcing the company to take measures to maintain its listing status.
- Historical Financial Data: Historical financial data for IM Cannabis indicates that despite its presence in the market, ongoing financial losses may affect its long-term sustainability strategy.
See More
IM Cannabis Closes $300,000 Convertible Note Financing
- Total Financing of $550,000: IM Cannabis Corp. successfully closed a $300,000 convertible note financing with an institutional investor, bringing the total gross proceeds from recent financings to $550,000, thereby enhancing the company's liquidity to support its operations.
- First Note Details: Under the agreement signed on April 6, 2026, IMC issued a $250,000 note to the lender with an 8% interest rate, increasing to 14% upon default, with repayment obligations satisfied solely through common share issuance, which could impact shareholder dilution.
- Second Note Terms: The second note amounts to $300,000 with the same 8% interest rate, and a conversion price set at $0.266 per common share, aimed at providing additional funding to support the company's medical cannabis operations in Israel and Germany.
- Warrant Issuance: IMC issued warrants for 272,861 and 1,127,820 shares in connection with the two notes, with exercise prices of C$0.47 and C$0.36 respectively, enhancing potential returns for investors while providing the company with additional capital sources.
See More
IM Cannabis Closes $300,000 Convertible Note Financing
- Financing Expansion: IM Cannabis Corp. has completed a $300,000 convertible note financing with an institutional investor, bringing total recent financing proceeds to $550,000, thereby enhancing the company's liquidity to support operations.
- Note Terms Details: The first note has a principal amount of $250,000 with an 8% interest rate, increasing to 14% upon default, and repayment obligations are satisfied through common stock issuance, reflecting the company's management of dilution risk for shareholders.
- Warrant Issuance: The warrants associated with the first note allow for the purchase of 272,861 common shares at an exercise price of C$0.47, enhancing potential returns for investors while providing additional capital sources for the company.
- Future Development Plans: The company intends to use the proceeds for general corporate purposes, indicating its ongoing expansion intentions in the medical cannabis market, particularly in Israel and Germany.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, needing to regain compliance by October 6, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days, highlighting the compliance pressure the company faces.
- Time Constraint: The company has 180 days to meet this requirement, and although the current share price is $0.3609, up 1.66% from the previous trading day, it remains significantly below the compliance threshold, which may affect investor confidence.
- Trading Impact: IM Cannabis stated that the notice has no immediate impact on its Nasdaq listing or trading, allowing its shares to continue trading on the Nasdaq Capital Market, providing the company with a buffer to regain compliance.
- Market Reaction: Despite facing compliance challenges, IM Cannabis's stock price saw a slight increase following the announcement, reflecting a cautiously optimistic market sentiment regarding the company's ability to restore compliance, which could influence its financing and market image.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating that its stock price has fallen below the minimum requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Regaining Compliance Deadline: The company has until October 6, 2026, to regain compliance, and if the stock price meets the requirement for ten consecutive trading days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Subsequent Compliance Opportunity: If compliance is not achieved within the initial 180 days, the company may apply for an additional 180-day compliance period, provided it meets other listing standards, indicating its commitment to maintaining its Nasdaq listing.
- Market Monitoring Strategy: IM Cannabis intends to closely monitor its stock price and consider measures during the compliance period to regain compliance, ensuring its continued listing status on Nasdaq.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Grace Period Arrangement: The company has until October 6, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days, with the possibility of an additional 180-day grace period if necessary.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing or trading, ongoing compliance pressure may undermine investor confidence, potentially impacting stock performance negatively.
- Strategic Response: The company intends to closely monitor its stock price and consider necessary actions to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing and enhancing shareholder value.
See More
IM Cannabis Reports Q1 Earnings Results
- Earnings Report: IM Cannabis reported a Q1 GAAP EPS of -$0.38, indicating challenges in profitability and reflecting pressure in a highly competitive market environment.
- Revenue Performance: The company generated revenue of $8.7 million, which, while showing some sales, falls short of industry expectations, potentially undermining investor confidence in future growth prospects.
- Nasdaq Notice: IM Cannabis received a notice from Nasdaq regarding minimum bid price requirements, which could negatively impact its stock liquidity and market perception, forcing the company to take measures to maintain its listing status.
- Historical Financial Data: Historical financial data for IM Cannabis indicates that despite its presence in the market, ongoing financial losses may affect its long-term sustainability strategy.
See More
IM Cannabis Closes $300,000 Convertible Note Financing
- Total Financing of $550,000: IM Cannabis Corp. successfully closed a $300,000 convertible note financing with an institutional investor, bringing the total gross proceeds from recent financings to $550,000, thereby enhancing the company's liquidity to support its operations.
- First Note Details: Under the agreement signed on April 6, 2026, IMC issued a $250,000 note to the lender with an 8% interest rate, increasing to 14% upon default, with repayment obligations satisfied solely through common share issuance, which could impact shareholder dilution.
- Second Note Terms: The second note amounts to $300,000 with the same 8% interest rate, and a conversion price set at $0.266 per common share, aimed at providing additional funding to support the company's medical cannabis operations in Israel and Germany.
- Warrant Issuance: IMC issued warrants for 272,861 and 1,127,820 shares in connection with the two notes, with exercise prices of C$0.47 and C$0.36 respectively, enhancing potential returns for investors while providing the company with additional capital sources.
See More
IM Cannabis Closes $300,000 Convertible Note Financing
- Financing Expansion: IM Cannabis Corp. has completed a $300,000 convertible note financing with an institutional investor, bringing total recent financing proceeds to $550,000, thereby enhancing the company's liquidity to support operations.
- Note Terms Details: The first note has a principal amount of $250,000 with an 8% interest rate, increasing to 14% upon default, and repayment obligations are satisfied through common stock issuance, reflecting the company's management of dilution risk for shareholders.
- Warrant Issuance: The warrants associated with the first note allow for the purchase of 272,861 common shares at an exercise price of C$0.47, enhancing potential returns for investors while providing additional capital sources for the company.
- Future Development Plans: The company intends to use the proceeds for general corporate purposes, indicating its ongoing expansion intentions in the medical cannabis market, particularly in Israel and Germany.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, needing to regain compliance by October 6, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days, highlighting the compliance pressure the company faces.
- Time Constraint: The company has 180 days to meet this requirement, and although the current share price is $0.3609, up 1.66% from the previous trading day, it remains significantly below the compliance threshold, which may affect investor confidence.
- Trading Impact: IM Cannabis stated that the notice has no immediate impact on its Nasdaq listing or trading, allowing its shares to continue trading on the Nasdaq Capital Market, providing the company with a buffer to regain compliance.
- Market Reaction: Despite facing compliance challenges, IM Cannabis's stock price saw a slight increase following the announcement, reflecting a cautiously optimistic market sentiment regarding the company's ability to restore compliance, which could influence its financing and market image.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating that its stock price has fallen below the minimum requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Regaining Compliance Deadline: The company has until October 6, 2026, to regain compliance, and if the stock price meets the requirement for ten consecutive trading days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Subsequent Compliance Opportunity: If compliance is not achieved within the initial 180 days, the company may apply for an additional 180-day compliance period, provided it meets other listing standards, indicating its commitment to maintaining its Nasdaq listing.
- Market Monitoring Strategy: IM Cannabis intends to closely monitor its stock price and consider measures during the compliance period to regain compliance, ensuring its continued listing status on Nasdaq.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Grace Period Arrangement: The company has until October 6, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days, with the possibility of an additional 180-day grace period if necessary.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing or trading, ongoing compliance pressure may undermine investor confidence, potentially impacting stock performance negatively.
- Strategic Response: The company intends to closely monitor its stock price and consider necessary actions to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing and enhancing shareholder value.
See More
